口腔黑色素瘤：临床进展与未来希望。

IF 1.1 Q4 ONCOLOGY

Clinical Advances in Hematology & Oncology Pub Date : 2023-08-01

Matthew C Perez, Jane L Messina, Lilit Karapetyan, Rogerio I Neves, Vernon K Sondak

{"title":"口腔黑色素瘤：临床进展与未来希望。","authors":"Matthew C Perez, Jane L Messina, Lilit Karapetyan, Rogerio I Neves, Vernon K Sondak","doi":"","DOIUrl":null,"url":null,"abstract":"Acral melanoma is a rare subtype of melanoma with unique histologic and biologic characteristics. Given its relative rarity compared with nonacral cutaneous melanoma, acral melanoma has been understudied and underrepresented in modern-day prospective clinical trials that have shaped the contemporary management of advanced cutaneous melanoma. Therefore, treatment principles for advanced acral melanoma are mostly derived from retrospective analyses or extrapolated from data largely based on nonacral cutaneous melanoma. Further studies are warranted to evaluate the efficacy of systemic immune and targeted molecular therapies, and to identify molecular targets for patients with advanced acral melanoma.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"21 8","pages":"400-409"},"PeriodicalIF":1.1000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acral melanoma: clinical advances and hope for the future.\",\"authors\":\"Matthew C Perez, Jane L Messina, Lilit Karapetyan, Rogerio I Neves, Vernon K Sondak\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Acral melanoma is a rare subtype of melanoma with unique histologic and biologic characteristics. Given its relative rarity compared with nonacral cutaneous melanoma, acral melanoma has been understudied and underrepresented in modern-day prospective clinical trials that have shaped the contemporary management of advanced cutaneous melanoma. Therefore, treatment principles for advanced acral melanoma are mostly derived from retrospective analyses or extrapolated from data largely based on nonacral cutaneous melanoma. Further studies are warranted to evaluate the efficacy of systemic immune and targeted molecular therapies, and to identify molecular targets for patients with advanced acral melanoma.\",\"PeriodicalId\":51585,\"journal\":{\"name\":\"Clinical Advances in Hematology & Oncology\",\"volume\":\"21 8\",\"pages\":\"400-409\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Advances in Hematology & Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

口角黑色素瘤是黑色素瘤的一种罕见亚型，具有独特的组织学和生物学特征。与非口腔皮肤黑色素瘤相比，口腔黑色素瘤相对罕见，因此在现代前瞻性临床试验中研究不足，代表性不强，而这些临床试验决定了晚期皮肤黑色素瘤的现代治疗方法。因此，晚期腋窝黑色素瘤的治疗原则大多来自回顾性分析，或主要根据非腋窝皮肤黑色素瘤的数据进行推断。我们有必要开展进一步的研究，以评估全身免疫疗法和靶向分子疗法的疗效，并确定晚期尖锐湿疣黑色素瘤患者的分子靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Acral melanoma: clinical advances and hope for the future.

Acral melanoma is a rare subtype of melanoma with unique histologic and biologic characteristics. Given its relative rarity compared with nonacral cutaneous melanoma, acral melanoma has been understudied and underrepresented in modern-day prospective clinical trials that have shaped the contemporary management of advanced cutaneous melanoma. Therefore, treatment principles for advanced acral melanoma are mostly derived from retrospective analyses or extrapolated from data largely based on nonacral cutaneous melanoma. Further studies are warranted to evaluate the efficacy of systemic immune and targeted molecular therapies, and to identify molecular targets for patients with advanced acral melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Advances in Hematology & Oncology ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.